期刊
SCIENCE OF THE TOTAL ENVIRONMENT
卷 731, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.scitotenv.2020.139064
关键词
Ozonation; Pharmaceuticals; Transformation products; Wastewater; Monitoring
资金
- INTERREG project CW Pharma
- BONUS CLEANWATER project
- BONUS (Art 185) - EU
- BONUS (Art 185) - Innovation Fund Denmark
- Sweden's innovation agency VINNOVA
- German Ministry for Education and Science (BMBF)
The removal of micropollutants from municipal wastewater is challenged by the number of compounds with diverse physico-chemical properties. Ozonation is increasingly used to remove micropollutants from wastewater. However, ozonation does not necessarily result in complete mineralization of the organic micropollutants but rather transforms them into new compounds which could be persistent or have adverse environmental effects. To explore ozone dose dependency of the formation and successive removal of ozonation products, two pilot-scale and one full-scale ozonation plants were operated subsequent to a conventional activated sludge treatment. The results from these trials indicated that the concentrations of several N-oxides, such as Erythromycin N-oxide, Venlafaxine N-oxide and Tramadol N-oxide, increased up to an ozone dose of 0.56-0.61 mg O-3/mg DOC while they decreased at elevated doses of 0.7-1.0 mg O-3/mg DOC. Similar results were also obtained for two transformation products of Diclofenac (Diclofenac 2,5-quinone imine and 1-(2,6-dichlorophenyl)indolin-2,3-dione) and one transformation product of Carbamazepine (1-(2-benzoic acid)-(1H,3H)-quinazoline-2,4-dione), where the highest concentrations appeared around 0.27-0.31 mg O-3/mg DOC. The formation maximum of a given compound occurred at a specific ozone dose that is characteristic for each compound, but seemed to be independent of the wastewater used for the experiments at the two pilots and the full-scale plant. (C) 2020 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据